394735-26-3

Basic information

• Product Name: (1R,2S,5S)-Methyl 3-((S)-2-(3-(t-butyl)ureido)-3,3-diMethyl butanoyl)-6,6-diMethyl-3-azabicyclo [3.1.0]hexane-2-carboxylate
• Synonyms: (1R,2S,5S)-Methyl 3-((S)-2-(3-(t-butyl)ureido)-3,3-diMethyl butanoyl)-6,6-diMethyl-3-azabicyclo [3.1.0]hexane-2-carboxylate;3-Azabicyclo[3.1.0]hexane-2-carboxylic acid, 3-[(2S)-2-[[(1,1-diMethylethoxy)carbonyl]aMino]-3,3-diMethyl-1-oxobutyl] -6,6-diMethyl-, Methyl ester, (1R,2S,5S)-;(1R,2S,5S)-3-[(2S)-2-[[(1,1-Dimethylethoxy)carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxylic acid methyl ester;3-[2-(3-tert-butylureido)-3,3-dimethylbutyryl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxylic acid methyl ester
• CAS NO: 394735-26-3
• Molecular Formula: C₂₀H₃₄N₂O₅
• Molecular Weight: 381.5096
• EINECS: -0
• Mol File: 394735-26-3.mol
• Article Data: 31

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (1R,2S,5S)-Methyl 3-((S)-2-(3-(t-butyl)ureido)-3,3-diMethyl butanoyl)-6,6-diMethyl-3-azabicyclo [3.1.0]hexane-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (1R,2S,5S)-Methyl 3-((S)-2-(3-(t-butyl)ureido)-3,3-diMethyl butanoyl)-6,6-diMethyl-3-azabicyclo [3.1.0]hexane-2-carboxylate(394735-26-3)
• EPA Substance Registry System: (1R,2S,5S)-Methyl 3-((S)-2-(3-(t-butyl)ureido)-3,3-diMethyl butanoyl)-6,6-diMethyl-3-azabicyclo [3.1.0]hexane-2-carboxylate(394735-26-3)

Safety Data

• Hazardous Substances Data: 394735-26-3(Hazardous Substances Data)

Usage

General Description

The chemical compound "(1R,2S,5S)-Methyl 3-((S)-2-(3-(t-butyl)ureido)-3,3-diMethyl butanoyl)-6,6-diMethyl-3-azabicyclo [3.1.0]hexane-2-carboxylate" is a complex molecule with a three-dimensional structure. It contains a methyl ester group, a ureido group, and a bicyclic azabicyclohexane ring. The compound is formed by the combination of various functional groups and has a unique stereochemistry. It is likely to have specific biological or pharmaceutical properties due to its intricate structure and potentially high potency as a drug or chemical agent.

Upstream product

• 672325-23-4 (1R,2S,5S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxylate methyl ester 
• 169870-82-0 2-((tert-butoxycarbonyl)amino)-3,3-dimethylbutanoic acid 
• 62965-35-9 N-tert-butyloxycarbonyl-L-tert-leucine 
• 219754-00-4 tert-butyl (1R,2S,5S)-2-(hydroxymethyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-3-carboxylate 
• 1026427-11-1 ((1R,2S,5S)-3-Benzyl-6,6-dimethyl-3-aza-bicyclo[3.1.0]hex-2-yl)-methanol 
• 103201-79-2 (3R,7aS)-3-phenyl-tetrahydro-pyrrolo[1,2-c]oxazol-5-one 
• 134107-65-6 (3R,7aS)-3-phenyl-3,7a-dihydro-1H-pyrrolo[1,2-c]oxazol-5-one 
• 219753-99-8 (1S,2S,4S,7R)-6-aza-3,3-dimethyl-8-oxa-7-phenyltricyclo<4.3.0.0>nonan-5-one 
• 219754-02-6 (1R,2S,5S)-3-(tert-butoxycarbonyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxylic acid 
• 569679-06-7 3-(tert-butyl) 2-methyl (1R,2S,5S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2,3-dicarboxylate 

Downstream Products

• 2628280-40-8 (1R,2S,5S)-N-{(1S)-1-cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-[3-methyl-N-(trifluoroacetyl)-L-valyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide 
• 394735-28-5 (1R,2S,5S)-N-(4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-(tert-butyl)ureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicylo[3.1.0]-hexane-2-carboxamide 
• 816444-90-3 (1R,2S,5S)-3-((S)-2-(3-tert-butylureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxylic acid 
• 394735-27-4 methyl (1R,2S,5S)-3-((S)-2-(3-(tert-butyl)-ureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxylate 
• 394730-60-0 boceprevir 
• 394735-37-6 (1R,2S,5S)-3-((S)-2-tert-butoxycarbonylamino-3,3-dimethylbutyryl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxylic acid 

Relevant articles and documents

FUNCTIONALIZED PEPTIDES AS ANTIVIRAL AGENTS

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

PROTEASE INHIBITORS FOR TREATMENT OR PREVENTION OF CORONAVIRUS DISEASE

Provided are protease inhibitor compounds that find use in treating or preventing coronavirus disease. In some embodiments, the coronavirus disease is COVID-19. Also provided are compositions and kits comprising the compounds, as well methods of using the

Discovery of potent sulfonamide P4-capped ketoamide second generation inhibitors of hepatitis C virus NS3 serine protease with favorable pharmacokinetic profiles in preclinical species

Hepatitis is a disease characterized by inflammation of the liver, usually producing swelling and, in many cases, permanent damage to liver tissues. Viral hepatitis C (HCV), a small (+)-RNA virus, infects chronically 3% of the world's population. Boceprevir, SCH 503034, (1) our first generation HCV inhibitor, has already established proof-of- concept and is currently in late stage (phase III) clinical trials. In view of the positive data from our first generation compound, further work aimed at optimizing its overall profile was undertaken. Herein, we report that extension of our earlier inhibitor to the P4 pocket by introducing a new sulfonamide moiety and optimization of the P1/P1′ capping led to the discovery of a novel series of inhibitors of the HCV NS3 serine protease. Optimization of the P1 residue significantly improved potency and selectivity. The combination of optimal moieties led to the discovery of compound 47 which, in addition to being a potent inhibitor of HCV subgenomic RNA replication, was also found to have good PK profile in rat, dog and monkey.